| Dr Doreen Kennedy Mclaughlin, MD | |
|
55 Fogg Rd, Weymouth, MA 02190-2432 | |
| (781) 340-4293 | |
| (781) 340-3782 |
| Full Name | Dr Doreen Kennedy Mclaughlin |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 55 Fogg Rd, Weymouth, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053326447 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 158888 (Massachusetts) | Primary |
| Entity Name | South Shore Hospital Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134227606 PECOS PAC ID: 4385546217 Enrollment ID: O20040122000304 |
News Archive
An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
The new 4th Edition of Practical Neurology, the respected "real-life" guide to diagnosing and managing neurologic disorders, has been completely rewritten to known neurologist and chair of the Department of Neurology of Loyola University Chicago Stritch School of Medicine.
KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.
› Verified 8 days ago
| Entity Name | South Shore Health Express Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477044212 PECOS PAC ID: 6406108836 Enrollment ID: O20181115000152 |
News Archive
An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
The new 4th Edition of Practical Neurology, the respected "real-life" guide to diagnosing and managing neurologic disorders, has been completely rewritten to known neurologist and chair of the Department of Neurology of Loyola University Chicago Stritch School of Medicine.
KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Doreen Kennedy Mclaughlin, MD 55 Fogg Rd, Weymouth, MA 02190-2432 Ph: (617) 624-8321 | Dr Doreen Kennedy Mclaughlin, MD 55 Fogg Rd, Weymouth, MA 02190-2432 Ph: (781) 340-4293 |
News Archive
An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
The new 4th Edition of Practical Neurology, the respected "real-life" guide to diagnosing and managing neurologic disorders, has been completely rewritten to known neurologist and chair of the Department of Neurology of Loyola University Chicago Stritch School of Medicine.
KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.
› Verified 8 days ago
Dr. James J Mensching, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 Washington Street, Weymouth, MA 02188 Phone: 781-626-5160 Fax: 781-803-2645 | |
Dr. Chris Michael Whelan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 Washington Street, Weymouth, MA 02188 Phone: 781-626-5160 Fax: 781-803-2645 | |
Catherine Helen Horwitz, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Fogg Rd, Weymouth, MA 02190 Phone: 781-624-8000 | |
Jeffrey A Johnson, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Fogg Rd, Weymouth, MA 02190 Phone: 781-340-8321 Fax: 781-340-4293 | |
George Lynch, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 55 Fogg Rd, Weymouth, MA 02190 Phone: 781-340-4293 Fax: 781-340-3782 | |
Dr. Brian Marcks, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Fogg Rd, Weymouth, MA 02190 Phone: 781-624-8000 Fax: 781-624-3609 |